Ultragenyx Pharmaceutical Inc.
RARE
$33.47
$0.100.30%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 630.60M | 610.16M | 590.69M | 560.23M | 522.75M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 630.60M | 610.16M | 590.69M | 560.23M | 522.75M |
| Cost of Revenue | 1.12B | 1.12B | 1.11B | 1.11B | 1.06B |
| Gross Profit | -494.32M | -507.79M | -522.31M | -554.35M | -537.58M |
| SG&A Expenses | 343.56M | 337.29M | 331.25M | 321.61M | 315.95M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.17B | 1.12B | 1.10B | 1.10B | 1.06B |
| Operating Income | -544.00M | -505.09M | -513.57M | -535.97M | -535.74M |
| Income Before Tax | -576.72M | -530.39M | -547.13M | -567.59M | -561.07M |
| Income Tax Expenses | 3.11M | 2.54M | 2.45M | 1.60M | -2.09M |
| Earnings from Continuing Operations | -579.83 | -532.93 | -549.58 | -569.18 | -558.99 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -579.83M | -532.93M | -549.58M | -569.18M | -558.99M |
| EBIT | -544.00M | -505.09M | -513.57M | -535.97M | -535.74M |
| EBITDA | -508.70M | -469.65M | -477.88M | -500.43M | -501.06M |
| EPS Basic | -5.94 | -5.53 | -5.88 | -6.34 | -6.46 |
| Normalized Basic EPS | -3.68 | -3.43 | -3.62 | -3.94 | -4.07 |
| EPS Diluted | -5.94 | -5.53 | -5.88 | -6.34 | -6.46 |
| Normalized Diluted EPS | -3.68 | -3.43 | -3.62 | -3.94 | -4.07 |
| Average Basic Shares Outstanding | 390.20M | 385.92M | 374.04M | 362.04M | 347.48M |
| Average Diluted Shares Outstanding | 390.20M | 385.92M | 374.04M | 362.04M | 347.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |